✦ LIBER ✦

Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies

✍ Scribed by Sandrine Faivre; Catherine Delbaldo; Valérie Boige; Patricia Pautier; Jean-Charles Soria; Fouad Namouni; Ronald Peck; Marvin Cohen; Eric Raymond

Book ID: 118435709
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 186 KB
Volume: 44
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2008.01.016

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

534 Ixabepilone, a novel tubulin interac

534 Ixabepilone, a novel tubulin interacting agent, given every other week in combination with irinotecan in patients with advanced malignancies: a phase i and pharmacokinetic study

✍ S. Faivre; C. Delbaldo; P. Pautier; V. Boige; S. Henriet; F. Namouni; C. Eyndels 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 136 KB

Phase I dose-escalating study of ES-285

Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors

✍ C. Massard, R. Salazar, J. P. Armand, M. Majem, E. Deutsch, M. García, A. Oaknin 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 591 KB

416 POSTER Phase I trial of ixabepilone

416 POSTER Phase I trial of ixabepilone administered as a 24-hour infusion in patients with advanced solid malignancies: updated safety profile and maximum tolerated dose

✍ A.R. Tan; T. Mekhail; M.J. Edelman; L.C. Iacono; M. Messina; O.C. Trifan 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 59 KB

A Phase I study of men-10755 in patients

A Phase I study of men-10755 in patients with a solid tumor as a shorti.v. infusion given once every 3 weeks

✍ Roelvink, M.; Aamdal, S.; Dombernowsky, P.; Wanders, J.; Peters, S.; Bortini, S. 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 136 KB

Phase I study of PM00104 (Zalypsis®) adm

Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors

✍ Massard, Christophe; Margetts, Jane; Amellal, Nadia; Drew, Yvette; Bahleda, Rati 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 171 KB

Spisulosine (ES-285) given as a weekly t

Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies

✍ P. Schöffski; H. Dumez; R. Ruijter; B. Miguel-Lillo; A. Soto-Matos; V. Alfaro; G 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 285 KB